Onegevity Health, Kirin and Mitsui collaborate for the development of unique nutritional products

onegevity-health-kirin-and-mitsui-collaborate-for-the-development-of-unique-nutritional-products
Representative Image

Earlier this year, Onegevity Health launched its first commercial product, Gutbio, to bring AI-based personalized insights and recommendations to help individuals manage and improve gut health.

Kirin Holdings Company, Mitsui & Co. and Onegevity Health, a market leader in advanced Artificial Intelligence (AI)-enabled insight solutions for prevention and wellness has announced a strategic collaboration to launch Onegevity Health’s testing system in Japan, as well as to develop unique nutritional products, leveraging the insights provided by Onegevity’s AI-based platform.

“We empower individuals to combine the best emerging research in the fields of microbiome and artificial intelligence to better manage chronic health issues,” said Onegevity Health CEO Paul Jacobson. “We create tools that keep individuals at the center of healthcare, with direct access to convenient, at-home testing and high-powered health intelligence to develop actionable, personalized plans for their health goals.”

Earlier this year, Onegevity Health launched its first commercial product, Gutbio, to bring AI-based personalized insights and recommendations to help individuals manage and improve gut health. Onegevity will expand services later this year to include whole-genome sequencing, blood testing, and data-driven nutritional product development. Mitsui and Kirin’s unique experience in developing international markets and innovative products, respectively, will accelerate Onegevity’s efforts to scale health intelligence in consumer markets.

“We are pleased to announce this strategic partnership with Onegevity to bring personalized health and wellness solutions that will strengthen the initiatives begun last year when Mitsui and Kirin made a joint strategic investment in our partner company Thorne,” said Masami Yokoyama, General Manager, NutriScience Division, Mitsui. “We will start our collaboration by launching Gutbio to accelerate our efforts in this space.”

“I believe Onegevity Health’s AI platform, which integrates multiple health-related data sources and generates insights from machine learning, provides us with crucial knowledge to develop new nutritional products, particularly in the pre- and pro-biotic spaces,” said Shinro Fujita, General Manager of Corporate Strategy, Kirin Holdings. “This strategic partnership reinforces our commitment to pursue data science to accelerate health insights, advance novel research concepts, and achieve precision in treatment, with the goal of improving customer outcomes.”

Based in New York, Onegevity Health delivers science-based, consumer-friendly recommendations for customized nutrition, clinically-studied supplements and pre- and pro-biotics to improve health outcomes. Onegevity provides a comprehensive molecular portrait and customized recommendations for an individual’s health based on integrated analysis of longitudinal blood, genetics, and microbiome profiles. Onegevity leverages partner company Thorne’s network of 35,000 physicians to offer convenient testing and powerful analytical tools to improve preventative care and lower healthcare costs for their patients.

Read Previous

NIN scientist gets elected as Fellow of the Royal Society of Chemistry

Read Next

Greenfield Capital Group Invests in AI TEA

Leave a Reply